Fig. 3

A Plasma PGRN concentrations across different clinical diagnoses. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001, two-tailed Mann–Whitney Test. Significant differences compared with controls are shown on the graph. Additionally, PGRN concentrations were significantly different for bvFTD v CBS (**), FTD-ALS (*), MCI (***) and PCA (**); lvPPA v PPA-NOS (**), FTD-ALS (***), MCI (****) and PCA (*); nfvPPA v CBS (*), FTD-ALS (***), MCI (**) and PCA (**); svPPA v PPA-NOS(**), CBS (*), FTD-ALS(**), MCI (****) and PCA (**); PPA-NOS v FTD-ALS (***), AD (*), LBD (*) and PCA (****); CBS v AD (**), LBD (*) and MCI (****); PSP v PCA (**); FTD-ALS v CBS (***), AD (**), LBD (**) and PCA (***); ALS v PCA (**); AD v MCI (****) and PCA (***); MCI v LBD (**) and PCA (****); LBD v PCA (**). (bvFTD: behavioural variant FTD, PPA: primary progressive aphasia, nfvPPA: nonfluent variant PPA, svPPA: semantic variant PPA, lvPPA: logopenic variant PPA, FTD-ALS: frontotemporal dementia—amyotrophic lateral sclerosis, ALS: amyotrophic lateral sclerosis, CBS: corticobasal syndrome, PSP: progressive supranuclear palsy, AD: Alzheimer’s disease, MCI: mild cognitive impairment, LBD: lewy body disease, PCA: posterior cortical atrophy). Small sample sizes in ALS (n = 1), PCA (n = 10), PPA-NOS (n = 11), FTD-ALS (n = 18), PSP (n = 16). B Plasma and C CSF PGRN concentrations in females and males in both GRN mutation carriers (GRN) and non-mutation carriers (non-GRN). * P < 0.05, ** P < 0.01, two-tailed Mann–Whitney Test. D Plasma PGRN concentrations in those with different GRN rs5848 and E TMEM106b rs1990622 polymorphisms in both GRN mutation carriers (GRN) and non-mutation carriers (non-GRN). * P < 0.05, ** P < 0.01, two-tailed Mann–Whitney Test. Error bars indicate standard error of the mean (SEM)